Health and Healthcare
IPO Withdrawal: ChemoCentryx (GSK)
Published:
Last Updated:
On Friday, ChemoCentryx Inc. filed to withdraw its pending registration for an IPO of up to $57.5 million. The market conditions of today are cited as the reasoning. The Mountain View, California-based company said in its filing, "At this time, due to current public market conditions, the Company has determined not to proceed with the initial public offering contemplated…"
ChemoCentryx is an emerging drug developer for autoimmune andinflammatory diseases, as well as oncology. Credit Suisse was the leadunderwriter and the company has raised $50 million in venture backingfrom GlaxoSmithKline (NYSE: GSK) to a total amount raised of what looksto be more than $150 million from Glaxo and other venture investors.
This form "RW’ for withdrawal may have been no surprise to most as the initial filing came on November 9, 2007.
JON C. OGG
NOVEMBER 17, 2008
Find a Qualified Financial Advisor (Sponsor)
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
